Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iloperidone
Drug ID BADD_D01134
Description Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Indications and Usage Treatment of acute schizophrenia.
Marketing Status approved
ATC Code N05AX14
DrugBank ID DB04946
KEGG ID D02666
MeSH ID C081732
PubChem ID 71360
TTD Drug ID D0M8VE
NDC Product Code 46016-1332; 43068-102; 51672-4178; 51672-4213; 43068-101; 43068-108; 51672-4180; 50379-0006; 63285-755; 63285-756; 66499-0067; 51672-4182; 0378-0632; 0378-0633; 43068-104; 43068-106; 43068-110; 66499-0042; 51672-4183; 0378-0631; 66022-0115; 43068-901; 51672-4181; 0378-0636; 43068-112; 43068-902; 0378-0634; 0378-0635; 43068-903; 0378-0630; 43068-113; 51672-4179; 51672-4184
UNII VPO7KJ050N
Synonyms iloperidone | Fanapt | HP 873 | HP-873 | Zomaril
Chemical Information
Molecular Formula C24H27FN2O4
CAS Registry Number 133454-47-4
SMILES CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Postmenopausal haemorrhage24.07.03.002; 21.02.01.002--Not Available
Major depression19.15.01.003--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Gastric pH decreased13.05.04.001--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Impulse-control disorder19.18.01.002--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Inner ear disorder04.04.02.002--Not Available
Urinary tract obstruction20.08.01.004--
Blood disorder01.05.01.004--Not Available
Drug intolerance08.06.01.0130.000287%Not Available
Psychotic disorder19.03.01.0020.000418%
Hepatobiliary disease09.01.08.003--Not Available
Acute kidney injury20.01.03.016--
Anal incontinence17.05.01.021; 07.01.06.029--
Gait inability17.02.05.069; 08.01.02.0110.000131%Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Intermenstrual bleeding21.01.01.015--Not Available
The 6th Page    First    Pre   6    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene